Loading...

Global Biotechnology And Digital Automation Will Drive Future Healthcare

Published
24 Nov 24
Updated
04 Sep 25
AnalystConsensusTarget's Fair Value
€147.53
20.2% undervalued intrinsic discount
04 Sep
€117.75
Loading
1Y
-25.6%
7D
-2.0%

Author's Valuation

€147.5320.2% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on04 Sep 25

Merck KGaA's consensus price target remains unchanged at €147.53 as analysts adopt a more neutral stance following disappointing Q2 results, lowered guidance, and reduced near-term growth visibility. Analyst Commentary Disappointing Q2 report and weaker-than-expected operational performance.

Shared on01 May 25
Fair value Decreased 15%

Shared on23 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Apr 25
Fair value Decreased 2.17%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25
Fair value Increased 13%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Decreased 11%

Shared on26 Mar 25
Fair value Decreased 0.81%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on19 Mar 25
Fair value Decreased 0.52%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on12 Mar 25
Fair value Increased 11%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.